Pfizer and the Challenges of the Global Pharmaceutical Industry 2013 (B)

    Research output: Other contributionEducation

    Abstract

    This is part of a case series. The case focuses on describing and analysing the environment, profitability and competitiveness of the global pharmaceutical industry, and to evaluate the current and future strategy of Pfizer. It features a large number of tables with quantitative data that help solving the case study. This document complements the (A) case and covers a description of the 10 largest pharmaceutical firms and highlights a number of strategic manoeuvres of major players in the last years. At the end, the reader is referred back to the Pfizer situation and Pfizer’s recent strategic initiatives and responses to the market changes.
    Original languageEnglish
    Publication date2013
    Place of PublicationCranfield
    PublisherCase Centre
    Number of pages7
    Publication statusPublished - 2013

    Cite this

    @misc{488ad680b73244acb820e900e4d44b2e,
    title = "Pfizer and the Challenges of the Global Pharmaceutical Industry 2013 (B)",
    abstract = "This is part of a case series. The case focuses on describing and analysing the environment, profitability and competitiveness of the global pharmaceutical industry, and to evaluate the current and future strategy of Pfizer. It features a large number of tables with quantitative data that help solving the case study. This document complements the (A) case and covers a description of the 10 largest pharmaceutical firms and highlights a number of strategic manoeuvres of major players in the last years. At the end, the reader is referred back to the Pfizer situation and Pfizer’s recent strategic initiatives and responses to the market changes.",
    author = "Nell, {Phillip Christopher}",
    note = "Case Study. Reference no.313-299-1",
    year = "2013",
    language = "English",
    publisher = "Case Centre",
    address = "United Kingdom",
    type = "Other",

    }

    Pfizer and the Challenges of the Global Pharmaceutical Industry 2013 (B). / Nell, Phillip Christopher.

    7 p. Cranfield : Case Centre. 2013, Case.

    Research output: Other contributionEducation

    TY - GEN

    T1 - Pfizer and the Challenges of the Global Pharmaceutical Industry 2013 (B)

    AU - Nell, Phillip Christopher

    N1 - Case Study. Reference no.313-299-1

    PY - 2013

    Y1 - 2013

    N2 - This is part of a case series. The case focuses on describing and analysing the environment, profitability and competitiveness of the global pharmaceutical industry, and to evaluate the current and future strategy of Pfizer. It features a large number of tables with quantitative data that help solving the case study. This document complements the (A) case and covers a description of the 10 largest pharmaceutical firms and highlights a number of strategic manoeuvres of major players in the last years. At the end, the reader is referred back to the Pfizer situation and Pfizer’s recent strategic initiatives and responses to the market changes.

    AB - This is part of a case series. The case focuses on describing and analysing the environment, profitability and competitiveness of the global pharmaceutical industry, and to evaluate the current and future strategy of Pfizer. It features a large number of tables with quantitative data that help solving the case study. This document complements the (A) case and covers a description of the 10 largest pharmaceutical firms and highlights a number of strategic manoeuvres of major players in the last years. At the end, the reader is referred back to the Pfizer situation and Pfizer’s recent strategic initiatives and responses to the market changes.

    M3 - Other contribution

    PB - Case Centre

    CY - Cranfield

    ER -